Absolute configuration and biological profile of pyrazoline enantiomers as MAO inhibitory activity by Goksen, Umut Salgin et al.
1 
 
 
 
 
ABSOLUTE CONFIGURATION and BIOLOGICAL PROFILE of 
PYRAZOLINE ENANTIOMERS as MAO INHIBITORY ACTIVITY  
 
 
Umut Salgin Goksen[a,b], Sevgi Sarıgul[c], Patrick Bultinck[d], Wouter Herrebout[e], Ilknur 
Dogan[c], Kemal Yelekci[f], Gulberk Ucar[g], Nesrin Gokhan Kelekci*[a] 
 
 
a Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Hacettepe University, 
06100 Sıhhiye, Ankara, Turkey. 
 b Turkish Medicines and Medical Devices Agency, Analyses and Control Laboratories, 
06100, Ankara, Turkey. 
c Chemistry Department, Bogazici University, Bebek, 34342 Istanbul, Turkey. 
d Department of Chemistry, Ghent University, Krijgslaan 281, S3, 9000 Gent, Belgium. 
e Department of Chemistry, University of Antwerp, Groenenborgerlaan 171, 2020 Antwerp, 
Belgium.  
f Department of Bioinformatics and Genetics, Faculty of Engineering and Natural Sciences, 
Kadir Has University, 34083 Fatih, Istanbul, Turkey. 
g Department of Biochemistry, Faculty of Pharmacy, Hacettepe University, 06100 Sıhhiye, 
Ankara, Turkey. 
 
*Corresponding author:  
Nesrin Gokhan Kelekci 
e-mail: onesrin@gmail.com, onesrin@hacettepe.edu.tr 
 
 
 
 
 
 
 
 
 
2 
 
Abstract 
A new racemic pyrazoline derivative was synthesized and resolved to its enantiomers using 
analytic and semipreparative high pressure liquid chromatography (HPLC). The absolute 
configuration of both fractions was established using Vibrational Circular Dichroism (VCD). 
The in vitro monoamine oxidase (MAO) inhibitory profiles were evaluated for the racemate 
and both enantiomers separately for the two isoforms of the enzyme. The racemic compound 
and both enantiomers were found to inhibit hMAO-A selectively and competitively. In 
particular, the R enantiomer was detected as an exceptionally potent and a selective MAO-A 
inhibitor (Ki = 0.85x10-3±0.05x10-3 µM and SI: 2.35x10-5) whereas S was determined as 
poorer compound than R in terms of Ki and SI (0.184±0.007 and 0.001). 
The selectivity of the enantiomers was explained by molecular modeling docking studies 
based on the PDB enzymatic models of MAO isoforms. 
 
Keywords: 2-Pyrazoline, Stereochemistry, Vibrational Circular Dichroism, Specific rotation,   
  Monoamine Oxidase Inhibitory Activity, Molecular Modelling Docking 
 
1 INTRODUCTION 
Monoamine oxidase (MAO) is a flavin adenine dinucleotide (FAD)-containing enzyme which 
is located in the outer mitochondrial membranes of neuronal, glial and other cells.[1,2] It 
catalyzes the oxidative deamination of biogenic amines in the brain [3]  and the peripheral 
tissues, regulating their level. [4], MAO exists in two forms, MAO-A and MAO-B. [4] MAO-A 
catalyzes the oxidative deamination of serotonin (5-HT), adrenaline (A), and noradrenaline 
(NA) and is selectively inhibited by the irreversible inhibitor clorgyline and the reversible 
inhibitor moclobemide. MAO-B catalyzes the oxidative deamination of phenylethylamine and 
benzylamine and is selectively inhibited by the irreversible inhibitor selegiline. [4,5] 
MAO-A and MAO-B play essential roles in vital physiological processes and are involved in 
the pathogenesis of various diseases in human. [6,7] Due to their key role, MAO inhibitors 
represent a useful tool for the treatment of several psychiatric and neurological diseases. In 
particular, reversible and selective MAO-A inhibitors are used as antidepressant and 
antianxiety drugs, while MAO-B inhibitors have been found to be useful as coadjuvants in the 
treatment of Parkinson’s disease (PD) and Alzheimer’s disease (AD). [8-15] 
The development of MAO inhibitors started with hydrazine derivatives. However, they were 
withdrawn due to their toxic side effects. [16] Subsequently, different families of heterocycles 
containing 2 or 4 nitrogen atoms were used as scaffolds for synthesizing reversible and 
selective monoamine oxidase inhibitors. [17-23] 2-Pyrazolines, which form one of these 
families, can also be considered as a cyclic hydrazine derivative. On the basis of the clinical 
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profiles of hydrazine and other heterocycles, researchers focused on structural modifications 
of the pyrazoline to enhance the pharmacological activity. Various pyrazoline derivatives 
were synthesized and screened for their monoamine oxidase (MAO), bovine serum amine 
oxidase (BSAO), semicarbazide sensitive amine oxidase (SSAO) activities. A considerable 
number of the prepared compounds were found to have BSAO, SSAO and MAO inhibitory 
activities comparable to or higher than the reference compounds. [24-34] 
 
In the light of the aforementioned findings and continuing our study of pyrazoline derivatives 
as potential inhibitors of MAO-A and MAO-B isoforms, we synthesized a series of 30 new 
pyrazoline derivatives which possess a stereogenic center on the five position of the ring and 
9 new hydrazon derivatives. New compounds were screened for their in vitro hMAO 
inhibitory activities using recombinant hMAO isoforms. All compounds inhibited hMAO-A 
potently, selectively and reversibly. Five compounds of these series exhibiting highest 
inhibitory potency and selectivity towards hMAO-A were assessed for acute and subchronic 
antidepressant effects using Porsolt’s forced swimming test (PFST) on mice. Our data 
elicited that they have an antidepressant-like action in mice by possibly interacting with the 
monoaminergic and serotonergic system [Umut Salgın Gökşen, Unpublished results].  
Then, we decided to do semipreparative chromatographic enantioseparation of the most 
potent and selective compound and to see the effect of the enantiomers on the MAO activity. 
We established the absolute configuration using VCD. To this end the R and S enantiomers 
of the biologically active 1-[2-(2-benzoxazolinone-3-yl)acetyl]-3-phenyl-5-(3,4-
dimethoxyphenyl)-4,5-dihydro-(1H)-pyrazole resolved on a chiral stationary phase were also 
submitted to in vitro biological evaluation. The results revealed that the R-enatiomer shows 
higher MAO-A inhibitory activity than the S-enantiomer. 
 
2 MATERIALS AND METHODS 
1. General information 
All chemicals and solvents used were purchased from Merck A.G. and Aldrich Chemical Co. 
The melting point of the new compound 5 was determined using a Thomas Hoover Capillary 
Melting Point Apparatus. The specific rotations of the enantiomers dissolved in acetone were 
determined using a Polarimeter Rudolph Autopol IV at 25 ºC operating at the sodium D line. 
The infrared (IR) spectra were obtained using a Perkin Elmer Spectrum One and a Nicolet 
520 FTIR spectrometer.  1H NMR spectra in dimethylsulfoxide (DMSO-d6) were recorded on 
a Bruker 400 MHz UltraShield spectrometer. Electron impact mass spectrometry of the 
sample in methanol was performed using a Waters 2695 Alliance Micromass ZQ LC/MS 
spectrometer. Elemental analysis (C, H, N) was performed using a LECO CHNS 932 
analyzer. The purity of the compound was assessed by TLC on silicagel HF254+366. 
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2. Synthesis and Structural Elucidation 
2-Benzoxazolinone (1), ethyl (2-benzoxazolinone-3-yl) acetate (2) and 2-(2-benzoxazolinone-
3-yl)acetylhydrazine (3) were synthesized according to previous methods. [35-37] 
1-Phenyl-3-(3,4-dimethoxyphenyl)-2-propen-1-one (4) (chalcone). Preparation of 4 was 
done according to a previously described method, [38] providing the chalcone (2.36 g, 88%). 
mp 86.5-88.5 ºC (from ethanol:water (3:1)) (lit., 88 ºC [39,40]).  
1-[2-(2-Benzoxazolinone-3-yl)acetyl]-3-phenyl-5-(3,4-dimethoxyphenyl)-4,5-dihydro-
(1H)-pyrazole (5). 2-(2-Benzoxazolinone-3-yl)acetylhydrazine 3 (1 mmol) was dissolved in 2 
mL of DMF and 20 mL of n-propanol. Chalcone 4 (1 mmol) and eight drops of hydrochloric 
acid were added to this solution and the latter refluxed for approximately 120 h.[41] The 
reaction mixture was then cooled and the precipitate was recrystallized to give the 4,5-
dihydro-(1H)-pyrazole (0.18 g, 13%) as a white crystal. mp 204-204.5 ºC (from acetone:water 
(3:1)). 
The purity of the synthesized compound was checked by elemental analysis. Its structure 
was determined using a combination of IR, 1H NMR, 13C NMR and ESI-MS. Both 
enantiomers exhibited identical IR, 1H NMR, 13C NMR and Mass spectra. 
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The IR, 1H NMR, 13C NMR and Mass spectral data are found to be: IR Vmax/cm-1: 3069, 3000, 
2944, 2839 (C-H), 1769, 1680 (C=O), 1603, 1520, 1490, 1439 (C=C, C=N), 1369, 1237, 
1140, 1020 (C-O-C, C-N); 1H NMR (400 mHz, DMSO-d6) δ (ppm) J (Hz); 3.24 (1H, dd, H-
13a, JAB:18.3 Hz, JAX:5.0 Hz), 3.716 (3H, s, H-17a), 3.722 (3H, s, H-18a), 3.91 (1H, dd, H-
13b, JAB:18.2 Hz, JBX:11.7 Hz), 5.10 (1H, d, H-8a, J:17.6 Hz), 5.26 (1H, d, H-8b, J:17.6 Hz), 
5.54 (1H, dd, H-14, JBX:11.6 Hz, JAX:5.0 Hz), 6.75 (1H, dd, H-20, J1:8.3 Hz, J2:1.9 Hz), 6.82 
(1H, d, H-16, J:1.9 Hz), 6.89 (1H, d, H-19, J:8.4 Hz), 7.13 (1H, t, H-5), 7.19 (1H, t, H-6), 7.28 
(1H, d, H-4, J45:7.6 Hz), 7.36 (1H, d, H-7, J67:7.7 Hz), 7.49-7.52 (3H, m, H-23 and H-24), 
7.86-7.88 (2H, m, H-22); 13C NMR (400 mHz, DMSO-d6) δ (ppm); 42.0 (C-13), 43.8 (C-8), 
55.4 (C-17a), 55.5 (C-18a), 59.9 (C-14), 109.4 (C-7), 109.5 (C-5 ve C-6), 111.9 (C-4), 117.3 
(C-16), 122.2 (C-19), 123.8 (C-20), 126.9 (C-23), 128.7 (C-22), 130.61 (C-24), 130.65 (C-
3a), 131.4 (C-21), 133.9 (C-15), 141.8 (C-7a), 148.0 (C-18), 148.8 (C-17), 154.0 (C-12), 
156.0 (C-2), 163.1 (C-9); ESI-MS m/z: 496 ([M+K]+, 3%), 481 ([M+H+Na]+, %31), 480 
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([M+Na]+, %100), 458 ([M+H]+), %17,) 320 ([M+-C6H3(OCH3)2]+, %17), 176 ([2-benzoks.-CH2-
CO]+, %13), 148 (2-benzoks.-CH2]+, %16). Found: C, 68.18; H, 5.06; N, 9.15. Calculated for 
C26H23N3O5: C, 68.26; H, 5.07; N, 9.19. 
3. Analytic Separation & Stereochemistry - HPLC analysis 
Liquid chromatography was performed using an ultraviolet (UV) detector Shimadzu SPD-6A 
(λ=254 nm) in combination with a CHIRALPAK AD-H column packed with amylose tris (3,5-
dimethylphenylcarbamate) (the column for the analyses had particle size 5 µm; column size 
250x4.6 mm, the semi-preparative column had particle size 5 µm; column size 250x10 mm) 
as stationary phase at 35 ºC. The chromatograms were recorded and the chromatographic 
peaks were integrated using the Shimadzu C-R6A Chromatopac software. 
4. Vibrational Circular Dichroism (VCD) spectra 
The stereochemistry of the separate enantiomers was determined by Vibrational Circular 
Dichroism (VCD). IR and VCD spectra of the compounds were obtained using a BioTools 
ChiralIR-2X dual PEM spectrometer. Solutions containing up to 3.0 mg of the samples from 
both fractions from the analytical separation were dissolved in CDCl3. Spectra were recorded 
in a 100 micron liquid cell equipped with BaF2 windows. For both enantiomers, 40000 scans 
were recorded at 4 cm-1 resolution and averaged. The analysis reported below is based on 
the experimental spectra of the first eluent. A virtual racemate was used for baseline 
subtraction.  Hence, spectra for the two enantiomers are exact mirror images.     
 
Extensive conformational analyses were performed using the MMFF94S [42] MMF [43] and 
SYBYL[44] force fields using the Monte Carlo and reservoir-filling algorithms, as 
implemented in the Spartan08 [45] and Conflex [46,47] software packages respectively. The 
geometries derived from the molecular mechanics simulations were optimized at the Density 
Functional Theory level using Gaussian 09 [48] using the B3LYP/6-31G* and B3LYP/cc-
pVTZ combinations of DFT functional and basis set and a SCRF model to account for 
solvent interactions.  Boltzmann weighted IR and VCD spectra were obtained by assuming 
Lorentzian band profiles with a FWHH of 10 cm-1. The Boltzmann populations used were 
based on the standard enthalpies obtained. Inspection of the data shows that enlarging the 
basis set from 6-31G* to cc-pVTZ only has a minor influence on the IR and VCD spectra. 
Both the experimental and theoretical spectra are shown in figure 1. 
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Figure 1.  Experimental and calculated IR and VCD spectra obtained for the R enantiomer of 
1-[2-(2-benzoxazolinone-3-yl)acetyl]-3-phenyl-5-(3,4-dimethoxyphenyl)-4,5-dihydro-1H-
pyrazole. For the experimental VCD spectra, the noise was added as a solid line in red.  Due 
to the use of a virtual racemate for baseline subtractions, the experimental spectra for the R 
and S enantiomers are perfect mirror images.   
 
 
5. Biochemistry  
Material 
Recombinant hMAOs and other chemicals were purchased from Sigma-Aldrich. The 
Amplex®-Red MAO assay kit was obtained from Molecular Probes (Invitrogen Detection 
Technologies), USA. 
Determination of MAO Activity  
The Amplex® Red MAO Assay Kit provides a one-step fluorometric method for the 
continuous measurement of MAO activity using a fluorescence microplate reader. [49,50]  
The assay is based on the detection of H2O2 in a horse radish peroxidase coupled reaction 
using the Amplex Red reagent, a highly sensitive and stable probe for H2O2. Since resorufin, 
the reaction product, has absorption and fluorescence emission maxima of 571 nm and 585 
nm, respectively, there is no significant interference from auto fluorescence. 
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Recombinant enzymes were diluted in a reaction buffer (containing 0.25 M of sodium 
phosphate, pH 7.4). 100 µL hMAO-A or MAO-B solution was incubated with 0.2 µL of 
inhibitor stock solution (clorgyline or pargyline, 0.5 mM) at room temperature for 30 min. 
Enzyme and inhibitor concentrations were kept as twofold lower in the final reaction volume. 
The positive control solution was prepared by diluting the 20 mM H2O2 working solution to the 
final concentration of 10 µM in the reaction buffer whereas the reaction buffer without H2O2 
was prepared as the negative control. The reaction was started by adding 100 µL of the 
Amplex Red reagent to each microplate well containing the samples and controls. The 
mixtures were incubated for 30 minutes at room temperature. The fluorescence was 
measured using excitation at 530 nm and emission at 590 nm at multiple time points to follow 
the kinetics of the reactions. Background fluorescence was corrected by subtracting the 
values derived from the control (no enzyme). The possible capacity of the new compounds to 
modify the fluorescence generated in the reaction mixture due to non-enzymatic inhibition 
was determined by adding these compounds to solutions containing only the Amplex Red 
reagent in a sodium phosphate buffer. The newly synthesized compounds were tested for 
their possible interactions with Amplex Red reagent according to the method previously 
decribed [49-51) and it was found that our compounds did not directly react with Amplex Red 
reagent. 
Kinetic Studies 
The synthesized derivatives were dissolved in dimethyl sulfoxide (DMSO), with a maximum 
concentration of 1% and used in a wide concentration range of 0.10-200.00 µM. The 
reference inhibitors were also dissolved in DMSO in a concentration range of 0.001-20.00 
µM. The mode of MAO inhibition was examined using Lineweaver-Burk plotting. The slopes 
of the Lineweaver-Burk plots were plotted versus the inhibitor concentration and the Ki values 
were determined from the x-axis intercept as -Ki. Each Ki value is the representative of single 
determination where the correlation coefficient (R2) of the replot of the slopes versus the 
inhibitor concentrations was at least 0.98. The selectivity index (SI) was calculated as 
Ki(hMAO-A)/Ki(hMAO-B). The protein concentration was determined according to the 
Bradford method. [52] 
Reversibility Studies 
The reversibility of the hMAO inhibition with the new compounds was determined by dialysis 
as previously described [53]. Dialysis tubing 16×25 mm (SIGMA) with a molecular weight cut-
off of 12000 Da and a sample capacity of 0.5-10 mL was used. Adequate amounts of the 
recombinant enzymes (hMAO-A or B) (1 U/mL) and the inhibitors at a concentration equal to 
fourfold the IC50 values for the inhibition of hMAO-A and -B, were incubated in a potassium 
phosphate buffer (0.05 M, pH 7.4, 5% sucrose containing 1% DMSO) for 15 min. at 37 ºC. 
Another set was prepared by preincubation of the same amount of hMAO-A and -B with the 
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reference inhibitors. The enzyme-inhibitor mixtures were subsequently dialyzed at 4 ºC in 80 
mL of the dialysis buffer (100 mM potassium phosphate, pH 7.4, 5% sucrose). The dialysis 
buffer was replaced with fresh buffer twice during the 24 hours of dialysis. After dialysis, 
residual MAO activities were measured and expressed as mean±SEM. For comparison, 
undialyzed mixtures of the MAOs and the inhibitors were included in the study. 
Cytotoxicity Studies 
The cell viability was determined by a MTT assay [54]. Human hepatoma cell line HepG2 
(Invitrogen) was used. The cells were exposed to 5R and 5S at the concentrations of 1, 5 
and 25 µM, and 0.1% DMSO as a vehicle control for 24 hours. Control cells treated with 
0.1% DMSO were used as 100% viability. [55] Results were expressed as mean±SEM. 
Differences are considered statistically significant at p<0.05. 
6. Molecular Modeling Studies 
The crystal structures of MAO-A and MAO-B were extracted from the PDB 
(http://www.rcsb.org, for MAO-A pdb code: 2Z5X; human monoamine oxidase in complex 
with harmine, resolution 2.2 Å [56] and for MAO-B pdb code: 2V5Z; human MAO-B in 
complex with inhibitor safinamide, resolution 1.6 Å [57]). Each structure was cleaned of all 
water molecules and inhibitors as well as all non-interacting ions before being used in the 
docking studies. The initial oxidized form of the FAD was used in all docking studies. For 
MAO-A and MAO-B, one of the two subunits was taken as the target structure. Using a fast 
Dreiding-like force field [58] each protein’s geometry was first optimized and then submitted 
to the “Clean Geometry” toolkit of the Discovery Studio (Accelrys, Inc.) for a more complete 
check. Missing hydrogen atoms were added based on the protonation state of the titratable 
residues at a pH of 7.4. The ionic strength was set to 0.145 and the dielectric constant was 
set to 10. The AutoDock Tools (vv. 1.5.4) (ADT) [59] graphical user interface program was 
employed to setup the enzymes for molecular docking. 
The 3D structures of the ligand molecules were built, optimized at PM3 level and saved in 
pdb format. The ADT package was also employed to generate the docking input files of the 
ligands. AutoDock 4.2.6 was used for all dockings; the detailed docking procedure has been 
given elsewhere [60] and the detailed procedure was reported in our earlier work [61]. 
 
RESULTS AND DISCUSSION 
1. Synthesis and characterization 
The synthesis pathway of 1-[2-(2-benzoxazolinone-3-yl)acetyl]-3-phenyl-5-(3,4-
dimethoxyphenyl)-4,5-dihydro-1H-pyrazole is given in Scheme 1. Treatment of 2-
benzoxazolinone 1 with ethyl chloroacetate in K2CO3/acetone gave the N-alkylated product 
ethyl (2-benzoxazolinone-3-yl) acetate 2. [35] The acid hydrazide 3 was prepared by the 
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reaction of ethyl (2-benzoxazolinone-3-yl) acetate and hydrazine hydrate in ethanol. [36,37] 
On the other hand, α,β–unsaturated carbonyl compound (chalcone) 4 was prepared by 
reacting 3,4-dimethoxybenzaldehyde and acetophenone under basic condition according to 
the Claisen-Schmidt condensation. [38] The reaction of hydrazide 3 with chalcone 4 in n-
propanol under acidic condition gave compound 1-[2-(2-benzoxazolinone-3-yl)acetyl]-3-
phenyl-5-(3,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole 5 (Scheme 1). 
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Scheme 1. Synthesis pathway of 1-[2-(2-benzoxazolinone-3-yl)acetyl]-3-phenyl-5-(3,4-
dimethoxyphenyl)-4,5-dihydro-1H-pyrazole 5. 
 
Both enantiomers exhibited identical IR, 1H NMR, 13C NMR and Mass spectra. The IR 
spectrum of 5 revealed two stretching bands at 1769 cm-1 and 1680 cm-1 due to the carbonyl 
function of the lactam and acetyl groups, respectively. C=C, C=N and C-O-C, C-N stretching 
bands were found near 1603-1439 cm-1 and 1369-1020 cm-1, respectively. The existence of 
the C=N stretching bands and disappearance of the N-H stretching bands proves the closure 
of the 4,5-dihydro-(1H)-pyrazole ring. Aromatic and aliphatic C-H stretching bands were 
observed near 3069-2839 cm-1. 
In the 1H NMR spectrum of 5, multiplet or doublet peaks belonging to the protons of aromatic 
rings were observed at 7.88-6.75 ppm. Three distinct doublet of doublets of the ABX system 
in the 4,5-dihydro-(1H)-pyrazole ring (a CH proton and two anisochronous protons of a CH2) 
appeared at 5.54-3.24 ppm. The CH (Hx) proton appeared at 5.54 ppm due to vicinal 
coupling with the two magnetically non-equivalent protons of the methylene group at position 
4 of the 4,5-dihydro-(1H)-pyrazole ring. The signals of HA and HB of the 4,5-dihydro-(1H)-
pyrazole ring were observed as doublet of doublets at 3.24 and 3.91 ppm, respectively. The 
CH2 protons between the 2-benzoxazolinone and 4,5-dihydro-(1H)-pyrazole ring resonated 
as a pair of doublet of doublets at 5.10 and 5.26 ppm. The signals for methoxy groups 
appeared at 3.72 ppm as two separate peaks. Additional support for the structure of 5 was 
provided by 13C NMR spectra. In the 13C NMR spectra the lactam and acetyl C=O groups 
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gave two peaks at around 156 and 163 ppm. The peak at 154 ppm in the 13C NMR spectrum, 
assigned to the C=N moiety confirms the closure of 4,5-dihydro-(1H)-pyrazole ring). The ions 
produced under electrospray ionization showed a characteristic [M+Na]+ ion peak as the 
base signal in the mass spectrum. 
 
2. Analytic Separation & Absolute configuration 
Since it is known that the two enantiomers of a chiral molecule may exhibit different 
biological activities [62-65] we have decided to separate both enantiomers to evaluate their 
separate selective human MAO inhibitory activities. This separation was achieved for both 
enantiomers of 5 using analytic and semipreparative HPLC. 
During the separation, the compound was dissolved in methanol and 30 µL was injected to 
the column. The choice of the eluent was done as follows: First, different ratios of 
hexane:ethanol mixtures were tried as the mobile phase, however, none of them could 
resolve the compound into its enantiomers. Therefore, it was decided to use a more polar 
mobile phase. When an ethanol:methanol mixture with 80:20 ratio was used, the resolution 
was again not achieved. The enantiomers were finally resolved analytically with the 
separation factor (α) of 1.36 when a 50:50 ethanol:methanol mixture was used as the eluent 
(flow rate 0.4 mL/min). The enantiomers were then collected by semi-preparative HPLC 
using an CHIRALPAK AD-H semi-preparative column under the same conditions. 100 µL 
multiple injections of the racemate afforded pure enantiomers (Figure 2). 
1. eluent (R-enantiomer): [α]25365 = +(25±3)) (c 0.0008 g/mL in acetone). 
2. eluent (S-enantiomer): [α]25365 = - (25±3)  (c 0.0009 g/mL in acetone). 
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Figure 2. HPLC chromatogram of 5 showing the 1st eluted, (retention time 43.29 min) and 
the 2nd eluted, (retention time 56.25 min) enantiomer at 35 ºC. Column: Chiralpak AD-H, 
Eluent (v/v) 50:50 ethanol:methanol flow rate: 0.4 mL/min (α) :1.36. 
 
The measurement of circular dichroism associated with molecular vibrational transitions is 
referred to as vibrational circular dichroism (VCD) [66-68]. The assignment of the absolute 
configuration of the collected enantiomers was performed using VCD. The experimental IR 
and VCD spectra for the first eluent and the calculated IR and VCD spectra for the R 
enantiomer obtained at the B3LYP/cc-pvTZ level are shown in the Figure 1. Due to the 
limited amount of sample available, the absorbances in IR are rather small and the 
corresponding VCD spectrum is characterized by a substantial noise level. However, in 
general good agreement is found in which most, if not all, of the characteristic features 
observed are reproduced by the calculations. The agreement between experiment and 
theory, allows the characterization of the absolute configuration of the first eluent as R and 
that of the second eluent as S.    
Numerical data confirming the assignment of the absolute configuration of the first eluent as 
the R enantiomer and the second eluent as the S enantiomer was obtained using the 
CompareVOA algorithm described in ref [69]. The B3LYP/cc-pVTZ IR similarity index, using a 
scaling factor for the calculated frequencies of 0.985, and based upon the 1000–1800 cm-1 
spectral range studied, is determined to be 65.1%. As IR spectra are the same for 
enantiomers, they also share the same value for the similarity index. Using the experimental 
spectrum of the first eluent, we computed the similarity index between this experimental 
spectrum and the theoretical spectra of the the R and S enantiomers. The results are 68.5 
and 19.6%, respectively, which leads to an enantiomeric similarity index of 48.9%. This 
establishes that the first eluent corresponds to the R enantiomer. The confidence level for the 
assignment, based on the localization of the current assignments with respect to the 
database of correct and incorrect assignments contained in the CompareVOA algorithm, is 
99%. All calculations and analysis were repeated at the B3LYP/  6-31G* level of theory and 
resulted in very similar results albeit slightly worse. Likewise, for the second eluent the 
CompareVOA algorithm revealed that it corresponds to the S enantiomer. 
The similarity index for IR is substantially lower than the values obtained in many other 
studies. This deviation, most probably, is related to the appearance of a broad intense 
spectral feature in the experimental spectrum near 1000 cm-1 while no such band is observed 
in the calculated spectra. The origin of this band could not be established but all 
spectroscopic data together clearly establish the (absolute) chemical structure of the 
compound. 
 
3. Biochemistry 
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The newly synthesized compound 5 (in racemic form) was screened for its inhibitory activity 
towards human recombinant MAO-A and -B. Specific enzyme activities were calculated as 
0.171±0.008 nmol/(mg.min) (n=3) for hMAO-A and 0.133±0.009 nmol/(mg.min) (n=3) for 
hMAO-B. The selectivity index (SI) was expressed as Ki(MAO-A)/Ki(MAO-B). 5 was found to 
inhibit hMAO-A selectively and competitively since the IC50 value for hMAO-A inhibition was 
calculated as 1.20±0.02 µM whereas the IC50 value for hMAO-B inhibition was calculated as 
425.88±16.45 µM. Its experimental SI (Ki(MAO-A)/ Ki(MAO-B)) was found to be 0.003.  
For the kinetic experiments, the catalytic rates of hMAO-A and -B at different p-tyramine 
concentrations were measured. Lineweaver–Burk graphs were constructed in the absence of 
the inhibitor, and in the presence of compound 5 or 5R or 5S and reference inhibitors. Since 
the lines are linear and intersect on the y-axis, compounds 5, 5R and 5S are suggested to be 
competitive inhibitors of hMAO-A which may interact within the catalytic site of hMAO-A. Ki 
values for hMAO-A and -B inhibition for 5 (racemic form) were determined as 0.91x10-
3±0.01x10-3 µM and 20.00±1.55 µM, respectively (Table 1). The experimental SI for 5 was 
found as 4.55x10-5 showing that it is a remarkably selective and potent MAO-A inhibitor.  
Turning to the individual isomers, isolated enantiomer 5R inhibited both hMAO-A and -B 
potently.  However, this compound was found to inhibit hMAO-A more potently (Ki = 0.85x10-
3±0.05x10-3 µM for hMAO-A). The experimental SI value of 5R was found as 2.35x10-5 
showing that this derivative is highly selective towards hMAO-A when compared with the 
kinetic data of moclobemide, a known selective MAO-A inhibitor (Table 1). The kinetic 
behavior of 5R is indicated in Figure 3. 5S also inhibited hMAO-A and -B potently. However, 
the SI of 5S was calculated as 0.001 which is poorer than that of compound 5R. The 
reversibility tests were carried out using the dialysis method. [70] Compound 5, and its 
enantiomers 5R and 5S appeared as reversible inhibitors of hMAO-A (Table 2). As seen in 
table II, moclobemide, a known selective MAO-A inhibitor, strongly inhibited hMAO-A. 
Following incubation of the enzyme with moclobemide, the remaining MAO-A activity was 
determined as 34.3±1.4%. hMAO-A activity was recovered up to 91.2±2.9% after dialysis 
indicating that the inhibition is reversible. 5R inhibited hMAO-A more potently than 
moclobemide (10.5±0.6%). MAO-A activity was recovered to 95.2±1.3% after dialysis 
indicating that the inhibition of hMAO-A with 5R is almost totally reversible.  
 
Table 1. Calculated and experimental Ki values corresponding to the inhibition of hMAO 
isoforms by 1-[2-(2-benzoxazolinone-3-yl)acetyl]-3-phenyl-5-(3,4-dimethoxyphenyl)-4,5-
dihydro-1H-pyrazole 5. 
 
Compound 
Calc. Ki 
value for 
MAO-A 
(µM) 
Calc. Ki 
value for 
MAO-B 
(µM) 
Calc. SI * 
Exp Ki value 
for MAO-A  
(µM)** 
Exp Ki value 
for MAO-B 
(µM)** 
Exp. SI * 
Inhibition 
type, 
selectivity, 
reversibility 
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5 (racemic) - - - 0.91x10
-
3±10-4 20.00±1.55 4.55x10
-5 
MAO-A, 
competitive, 
reversible 
5R 0.74x10
-
3 29.47 
2.51x10-
5 
0.85x10-
3±0.05x10-3 36.20±1.86 2.35x10
-5 MAO-A, 
competitive, 
reversible 5S 0.229 193.25 0.001 0.184±0.007 175.00±9.30 0.001 
Selegiline 
(MAO-B 
inhibitor) 
22.02 34.07 0.646 9.060±0.44 0.09±0.004 100.67 
MAO-B,  
suicide 
inhibitor 
irreversible 
Moclobemide 
(MAO-A 
inhibitor) 
5.71 250.74 0.023 0.005±0.001 1.22±0.08 0.004 
MAO-A, 
competitive, 
reversible 
 * Selectivity index calculated as Ki(MAO-A)/Ki(MAO-B). The Selectivity towards MAO-A increases as the 
corresponding SI decreases while selectivity towards MAO-B isoform increases as the corresponding SI 
increases.  
** Each value represents the mean±standard error of mean (SEM) of three independent experiments. 
 
(a) 
 
 
 
(b) 
y = 0,0011x + 0,0011
R² = 0,9764
0
0,001
0,002
0,003
0,004
0,005
-1 -0,5 0 0,5 1 1,5 2 2,5
Sl
op
e
[I], nM
 
Figure 3. (a) Lineweaver–Burk plots for the inhibition of hMAO-A by 5R. [S]: substrate 
concentration (mM), [V]: reaction velocity (nmol/hour/mg). Inhibitor concentrations are shown 
at the left. (b) The second graph represents the plots of the slopes of the Lineweaver–Burk 
plots versus inhibitor concentration [I]. Ki was calculated as 0.85x10-3±0.05x10-3nM.  
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Table 2. Reversibility of the inhibition of hMAOs by the novel compounds.  
* Each value represents the mean±SEM (n=3).  
 
In vitro cytotoxicity of the new inhibitors was tested at three different concentrations (1, 5 and 
25 µM) (Table 3). The results showed that they are not toxic to hepatic cells at the test 
concentrations. 
 
Table 3. In vitro cytotoxicity of 1-[2-(2-benzoxazolinone-3-yl)acetyl]-3-phenyl-5-(3,4-
dimethoxyphenyl)-4,5-dihydro-1H-pyrazole  derivatives. 
Compound Viability (%) 1 µM 5 µM 25 µM 
5 95.26±1.52 92.25±2.01 89.26±1.77 
5R 97.45±1.30 95.22±1.85 90.22±1.97 
5S 93.56±2.13 90.55±1.03 88.77±2.01 
Data was expressed as mean±SEM (n=3). Cell viability was expressed as a percentage of the control value. 
p<0.05 was considered as statistically significant (* p<0.05, ** p<0.01, *** p<0.001 vs control). 
 
4. Molecular Modeling Docking Studies 
To rationalize the mode of interaction and the impact of the absolute configuration, molecular 
modeling docking studies were performed. Figures 4a-d show the result of the molecular 
modeling docking of 5R and 5S within the MAO-A active site. Analysis of the binding modes 
for the R isomer in the MAO-A active site cavity revealed that 5R is located in front of the 
FAD cofactor from re face. 5R interacts with the active site residues lining the cavity as well 
as the FAD cofactor effectively (Figure 4a) (Ki = 738.93 pM). Two hydrogen bonds occur 
between the side chain amine hydrogens of Lys 305 and the methoxy moieties of the phenyl 
group of the inhibitor. An additional hydrogen bond forms between the carbonyl groups of the 
inhibitor and the cofactor FAD (green dashed-line in Figure 4c). In addition to these 
significant interactions, four π-π interactions were identified between the side chain of 
Tyr407, Tyr444 and the benzoxazolinone ring of the inhibitor (pink dashed-line in Figure 4c).  
Also, in the 2D picture (Figure 4c) 5R enters various Van der Waals interactions with Ile180, 
Asn181, Lys305, Ileu335, Phe352, Tyr69, Gln215, Tyr197, Asp339, Lys218, Ala68, Gly67, 
Leu337, Phe208 and Gly443, amino acids. 
As shown in Figure 4b, enantiomer 5S is located at the active site of MAO-A (Ki = 229.44 
Test 
compound 
incubated with 
hMAO 
hMAO-A 
activity before 
dialysis 
(%) 
hMAO-A 
activity after 
dialysis 
(%) 
hMAO-B 
activity before 
dialysis 
(%) 
hMAO-B 
activity after 
dialysis 
(%) 
Reversibility 
With no 
inhibitor 100±0.00 100±0.00 100±0.00 100±0.00  
Moclobemide 34.28±1.37 91.22±2.88 75.29±3.01 92.00±4.00 Reversible 
Selegiline 91.31±2.84 92.16±3.14 50.29±1.66 51.02±2.30 Irreversible 
5 39.22±1.13 92.45±2.34 87.26±2.60 94.11±3.27 Reversible 
5R 10.46±0.54 95.21±1.33 79.50±2.46 94.00±2.14 Reversible 
5S 30.55±1.68 93.00±2.11 80.60±2.16 91.33±2.00 Reversible 
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nM). The 2-benzoxazolinone ring cannot make effective π-π bonds with Tyr407 and Tyr444 
since it cannot approach to FAD ring as in the case of 5R isomer. The 3,4-dimethoxyphenyl 
ring of 5S makes one π-σ interaction with Tyr197 and one π-π with Tyr407. The phenyl ring 
at position 3 of the 2-pyrazoline ring makes two π-alkyl interactions with Leu335 and Ile180 
and π- π interaction with Phe208. Figures 4b and 4d show that the inhibitor enters several 
Van der Waals interactions with Asn181, Lys305, Ileu335, Phe352, Tyr69, Gly443 and 
Thr408 amino acids.  
The experimental data given in Table 1 agree with these observations. All of the 
computational inhibition results support that the MAO-A inhibitory potency of the R 
enantiomer (Ki = 0.74x10-3 µM) is much higher and 310 times more selective in comparison 
to the S enantiomer (Ki = 0.229 µM). 
 
Figure 4. 3D representations of docked poses of the 5R isomer (a) and the 5S isomer (b) in 
the MAO-A active site. 2D interaction diagrams of the 5R isomer (c) and the 5S isomer (d) 
with amino acid residues lining the MAO-A active site. 
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Figure 5.  The 5R (magenta) and 5S (green) isomers superimposed within the active site of 
MAO-A isozyme. Chiral hydrogens are shown in white color, they are oriented differently in 
the active site of the enzyme.  
 
 
In Figure 5 5R and 5S were superimposed within the MAO-A active site. As figure 5 shows, 
the benzoxazolinone ring of 5R orients itself in the hydrophobic cage surrounded by Tyr407, 
Tyr444 and the FAD cofactor making four π-π interactions. In the case of 5S, the 3,4-
dimethoxyphenyl ring of the 5S occupies the same volume of the hydrophobic cage making 
only one π-σ interaction. The other moieties of the 4,5-dihydro-(1H)-pyrazole ring of both 
isomers do not overlap in the active site of the enzyme either. Having stereogenic center in 5 
results in a very different binding mode and significant inhibition constant difference. 
 
In Figure 5 5R and 5S were superimposed within the MAO-A active site. As figure 5 shows, 
the benzoxazolinone ring of 5R orients itself in the hydrophobic cage surrounded by Tyr407, 
Tyr444 and the FAD cofactor making four π-π interactions. In the case of 5S, the 3,4-
dimethoxyphenyl ring of the 5S occupies the same volume of the hydrophobic cage making 
only one π-σ interaction. The other moieties of the 4,5-dihydro-(1H)-pyrazole ring of both 
isomers do not overlap in the active site of the enzyme either. Figure 4 (c and d) shows the 
interaction diagram reflected in 2D pictures. It was seen from the figure 5, the chiral 
hydrogen of 5R makes a carbon hydrogen bond between the chiral hydrogen and Gln215 
amino acid residue, on the other hand this interaction is absent in 5S isomer. Having 
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stereogenic center in 5 results in a very different binding mode and significant inhibition 
constant difference between R and S stereoisomer. 
 
CONCLUSION 
1-[2-(2-benzoxazolinone-3-yl)acetyl]-3-phenyl-5-(3,4-dimethoxyphenyl)-4,5-dihydro-(1H)-
pyrazole (5) was synthesized and separated by analytic and semipreparative HPLC 
technique and evaluated for in vitro inhibitory profiles of both enantiomers and the racemate 
towards hMAOs. Racemic 5 was found to inhibit hMAO-A selectively and competitively. 
According to the expectation that the chiral center may lead to different ligand enzyme 
interactions, the separate enantiomers were resubmitted to in vitro biological evaluation. 
Isolated enantiomers 5R and 5S were also found to be selective MAO-A inhibitors.  The 
experimental selectivity index was found to be 2.35x10-5 for 5R showing that this derivative is 
a highly selective and potent MAO-A inhibitor compared to moclobemide. A molecular 
modeling docking study was carried out using PDB enzymatic models in order to evaluate 
the molecular interactions of the enantiomers with hMAO isoforms. 5R appeared as the more 
potent and selective MAO-A inhibitor when compared to 5S. This indicates that 5R interacts 
more strongly with the active site of MAO-A than 5S. The key factor for the efficient and 
selective activity is, most probably, the shorter distance between 5R and the FAD ring at the 
active site of MAO. 
In summary, the results show that seperated enantiomers of the the newly synthesized 4,5-
dihydro-(1H)-pyrazole derivative may be promising candidates as potent MAO-A inhibitor 
agents. These findings may assist medicinal chemists working in this area and in vivo studies 
on mice have recently been initiated. 
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